Area of research
Economics and Econometrics · Cardiology and Cardiovascular Medicine
Research interest
Research interests include Atrial Fibrillation Management and Outcomes, Pharmaceutical Economics and Policy, Health Systems, Economic Evaluations, Quality of Life, and Neuropeptides and Animal Physiology.
Platelets fine-tune effector responses of naïve CD4+ T cells via platelet factor 4-regulated transforming growth factor β signaling
Sex differences in spontaneous reports on adverse drug events for common antihypertensive drugs
Thrombin‐reduced miR‐27b attenuates platelet angiogenic activities in vitro via enhancing platelet synthesis of anti‐angiogenic thrombospondin‐1
The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations
High adherence to the ‘Wise List’ treatment recommendations in Stockholm: a 15-year retrospective review of a multifaceted approach promoting rational use of medicines
Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation
Differential Impact of Selective Serotonin Reuptake Inhibitors on Platelet Response to Clopidogrel: A Randomized, Double‐Blind, Crossover Trial
Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma
Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate
Personalizing health care: feasibility and future implications
Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs
Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations
Therapeutic drug monitoring for tomorrow